

GLAXOSMITHKLINE PLC  
Form 6-K  
October 18, 2016

FORM 6-K

SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934

For period ending 17 October 2016

GlaxoSmithKline plc  
(Name of registrant)

980 Great West Road, Brentford, Middlesex, TW8 9GS  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F  Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the  
Securities Exchange Act of 1934.

Yes No

GlaxoSmithKline plc (the 'Company')

Transaction notification

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Dr M M Slaoui  
 b) Position/status Chairman, Global Vaccines  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

- a) Description of the financial instrument American Depositary Shares ('ADSs')  
 ISIN: US37733W1053  
 Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Performance Share Plan.
- b) Nature of the transaction
- c) Price(s) and volume(s)
- | Price(s) | Volume(s) |
|----------|-----------|
| \$42.39  | 1414.687  |
| \$42.39  | 1569.750  |
| \$42.39  | 1797.585  |

Aggregated information

- d) Aggregated volume 4,782.022  
 Price \$42.39

- e) Date of the transaction 2016-10-13

- f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

- a) Name Mr N Hirons  
 b) Position/status SVP, Global Ethics & Compliance  
 c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

- a) Name GlaxoSmithKline plc

b) LEI 5493000HZTVUYLO1D793  
 Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 ISIN: US37733W1053  
 Increase in notional interest  
 in ADSs following the  
 re-investment of dividends  
 b) Nature of the transaction paid to shareholders on 13  
 October 2016 on ADSs held  
 in the Company's 2009  
 Performance Share Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
 \$42.39 85.247

Aggregated information

d) Aggregated volume n/a (single transaction)  
 Price

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

1. Details of PDMR/person closely associated with them ('PCA')

a) Name Mr B McNamara  
 b) Position/status CEO, GSK Consumer  
 Healthcare

c) Initial notification/  
 amendment Initial notification

2. Details of the issuer, emission allowance market participant, auction  
 platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

Details of the transaction(s): section to be repeated for (i) each type of  
 3. instrument; (ii) each type of transaction; (iii) each date; and (iv) each  
 place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 ISIN: US37733W1053  
 Increase in notional interest  
 in ADSs following the  
 re-investment of dividends  
 b) Nature of the transaction paid to shareholders on 13  
 October 2016 on ADSs held  
 in the Company's 2009  
 Performance Share Plan.

c) Price(s) and volume(s) Price(s) Volume(s)  
 \$42.39 42.422

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

|         |         |
|---------|---------|
| \$42.39 | 71.440  |
| \$42.39 | 211.994 |
| \$42.39 | 357.084 |
| \$42.39 | 551.108 |

Aggregated information

|   |  |
|---|--|
| d) Aggregated volume  | 1234.048   |
| Price   | \$42.39  |
| e) Date of the transaction  | 2016-10-13   |
| f) Place of the transaction   | n/a  |
| 1. Details of PDMR/person closely associated with them ('PCA')  |  |
| a) Name   | Mr D E Troy  |
| b) Position/status  | SVP & General Counsel  |
| c) Initial notification/<br>amendment   | Initial notification   |
| 2. Details of the issuer, emission allowance market participant, auction<br>platform, auctioneer or auction monitor   |  |
| a) Name   | GlaxoSmithKline plc  |
| b) LEI  | 5493000HZTVUYLO1D793   |
| 3. Details of the transaction(s): section to be repeated for (i) each type of<br>instrument; (ii) each type of transaction; (iii) each date; and (iv) each<br>place where transaction(s) has been conducted |  |
| a) Description of the financial instrument  | American Depositary Shares<br>(‘ADSs’)<br>ISIN: US37733W1053<br>Increase in notional interest<br>in ADSs following the<br>re-investment of dividends |
| b) Nature of the transaction  | paid to shareholders on 13<br>October 2016 on ADSs held<br>in the Company's 2009<br>Performance Share Plan.  |
| c) Price(s) and<br>volume(s)  | Price(s)      Volume(s)  |
|   | \$42.39      876.858   |
|   | \$42.39      972.968   |
|   | \$42.39      1128.822  |

Aggregated information

|  |   |
|--|---|
| d) Aggregated volume   | 2978.648  |
| Price  | \$42.39   |
| e) Date of the transaction                                     | 2016-10-13  |
| f) Place of the transaction                                    | n/a   |
| 1. Details of PDMR/person closely associated with them ('PCA') |   |
| a) Name  | Dr K Slaoui   |
| b) Position/status   | PCA of Dr M M Slaoui<br>(Chairman, Global Vaccines) |
| c) Initial notification/<br>amendment                          | Initial notification                                |

amendment

2. Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a) Name GlaxoSmithKline plc  
 b) LEI 5493000HZTVUYLO1D793

3. Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a) Description of the financial instrument American Depository Shares ('ADSs')  
 ISIN: US37733W1053

b) Nature of the transaction Increase in notional interest in ADSs following the re-investment of dividends paid to shareholders on 13 October 2016 on ADSs held in the Company's 2009 Performance Share Plan.

|                           |          |           |
|---------------------------|----------|-----------|
| c) Price(s) and volume(s) | Price(s) | Volume(s) |
|                           | \$42.39  | 22.991    |
|                           | \$42.39  | 24.324    |
|                           | \$42.39  | 25.675    |

Aggregated information

d) Aggregated volume 72.99  
 Price \$42.39

e) Date of the transaction 2016-10-13

f) Place of the transaction n/a

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

GlaxoSmithKline plc  
 (Registrant)  
 Date: October 17, 2016

By: VICTORIA WHYTE  
 -----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc